Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2007

View Archived Issues

New therapeutic agents for neurological disorders reported in recent patents

Novel therapeutic agents for cardiovascular disorders imparted in recent patents

New therapeutics for cancer covered in recent patent literature

Angptl4 validated as a drug target in cardiovascular disorders

PRT-054021 prevents venous thromboembolism after knee replacement

Tolevamer liquid fails to meet primary endpoint in CDAD trial

Roche and Alnylam form alliance in RNAi therapeutics

Bristol-Myers Squibb terminates MIV-170 license agreement with Medivir

Prolonged treatment with amylin mimetic peptide slows gastric emptying and improves glucose control

PTP1B inhibition improves insulin sensitivity via increases in adiponectin in obese monkeys

ProEthic files NDA for PRO-513 for migraine headaches

Silence Therapeutics and AstraZeneca to codevelop siRNA molecules

BHI-001: a novel Hsp90 inhibitor with improved therapeutic index

GW and Otsuka collaborate to research and develop cannabinoids

Clavis Pharma's phase II combination study of Elacyt approved

Positive results for transdermal delivery of hPTH (1-34) in phase I trials

Hsp32 validated as a therapeutic target in systemic mastocytosis

SPA agreement for pivotal study of oral Fodosine in cutaneous T-cell lymphoma

Japanese launch for Nesp

Positive preclinical results of new CRAC channel inhibitor in models of allergic inflammation

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...